Abstract
There are a number of recent studies detailing the transmission of SARS-CoV-2 (Covid-19) via both Droplet and Aerosol airborne particle routes of infection. Because of this, it is necessary to understand the release of different sized particles in activities such as playing brass instruments in order for an analysis of risk to take place for such activities. In this investigation, the quantity and size of particles released by brass instruments while they are played was analysed for 7 different types of brass instrument. This was contrasted with the same individuals breathing as a comparison for more general activities as well as the effect of a mitigating polycotton barrier over the end of their instruments. To investigate the particles released, the particles were size sorted and counted with a six-channel laser particle counter. Multiple measurements were made by each individual in each condition investigated. The mean concentration exiting across all instruments measured was found to be 1.21x107±1.03x106 Aerosol type particles/m3 and 1.43x104±9.01x102 Droplet type particles/m3 per minute. When breathing, the mean count was 1.61x107±1.33x106 Aerosol type particle/m3 and 5.45x103±1.20x103 Droplet type particles/m3. When playing with a barrier cover, the mean number of particles emitted fell to 2.60x106±2.11x105 Aerosol type particle/m3 and 5.20x103±8.02x102 Droplet type particles/m3. This barrier represented an average 78.5% reduction for the number of respiratory Aerosol type particles and 63.8% reduction for Droplet type particles compared to playing an instrument without the barrier covering. It was investigated what effect playing for a more extended period of time had on the release of particles with comparisons made to singing, breathing and covering the instruments' bell ends with a barrier cap. This showed that the mean number of Aerosol type particles produced while playing was 5.38x107±3.15x106 Aerosol type particles/m3 produced and showed a significant drop in Aerosol type particle production when playing with a barrier used, with a mean average of 2.28x106±8.01x104 Aerosol type particles/m3. Both breathing and singing showed consistent numbers of Aerosol type particles produced with means of 6.59x107±7.94x105 Aerosol type particles/m3 and 5.28x107±5.36x105 Aerosol type particles/m3 respectively. This showed a drop in mean Aerosol type particles/m3 of 95.7% when using a barrier cap compared to playing without a barrier. It is concluded that, while playing a brass instrument, the propagation of respiratory Aerosols does occur and, to a smaller extent, so do Droplet size particles, but at a lower level than when the subject was breathing without an instrument. Finally, it was shown that the use of a barrier cap on the bell end of the instrument offers a significant reduction in the production of respiratory Aerosols into the immediate surroundings, which offers a possible mitigation method for playing in groups from the release of Aerosol type particles, especially in hard to ventilate spaces.
Competing Interest Statement
The authors have declared working for Brass Bands England, which exists to support brass bands in England and the wider UK.
Funding Statement
This study was supported by funds from Arts Council England covering salary support for AP and KC. The cleanroom facility and particle counter were provisioned by Centre Stage Ltd. The funders did not have a role in the experimental design, data collection, analysis or decision to publish and content of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from Brass Bands England's Board and informed consent was obtained in writing from all participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
